GRAIL, LLC (GRAL)vsThermo Fisher Scientific Inc (TMO)
GRAL
GRAIL, LLC
$61.64
-2.03%
HEALTHCARE · Cap: $2.69B
TMO
Thermo Fisher Scientific Inc
$465.00
-1.99%
HEALTHCARE · Cap: $176.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 30610% more annual revenue ($45.20B vs $147.17M). TMO leads profitability with a 15.1% profit margin vs -277.5%. TMO earns a higher WallStSmart Score of 62/100 (C+).
GRAL
Hold36
out of 100
Grade: F
TMO
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRAL.
Margin of Safety
-16.1%
Fair Value
$408.60
Current Price
$465.00
$56.40 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -16.1% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GRAL profiles as a turnaround stock while TMO is a mature play — different risk/reward profiles.
GRAL is growing revenue faster at 14.0% — sustainability is the question.
TMO generates stronger free cash flow (816M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TMO scores higher overall (62/100 vs 36/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology innovator specializing in groundbreaking blood tests for early cancer detection, leveraging its proprietary genomic technologies to transform the multi-cancer early detection (MCED) landscape. By providing individuals with crucial insights for proactive health management, GRAIL is committed to advancing precision medicine and significantly improving patient outcomes. The company's pioneering efforts aim to fill critical gaps in existing cancer screening and diagnostics, solidifying its position as a vital entity in the evolving oncology sector.
Visit Website →Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?